Therapy Areas: Inflammatory Diseases
Kancera and Recardio sign letter of intent for licensing agreement
7 March 2025 - Kancera AB (Nasdaq First North Premier Growth Market:KAN), a developer of anti-inflammatory drugs in the field of cardiovascular diseases, said on Friday that it has signed a letter of ...
Dermata Therapeutics completes treatment in XYNGARI Phase 3 acne trial
5 March 2025 - Dermata Therapeutics Inc (Nasdaq: DRMA, DRMAW), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, announced on Tuesday ...
Shed launches Low-Dose Naltrexone
5 March 2025 - Telehealth clinic Shed announced on Tuesday that it has introduced Low-Dose Naltrexone (LDN), a therapeutic solution for individuals managing chronic pain, autoimmune diseases and metab...
GSK demonstrates significant improvement in CRSwNP treatment with depemokimab at 2025 AAAAI
3 March 2025 - Biopharmaceutical company GSK plc (LSE/NYSE: GSK) announced on Monday that it presented positive results from its ANCHOR-1 and ANCHOR-2 phase III trials at the 2025 AAAAI/WAO Joint Cong...
Avirmax Biopharma starts IND-enabling studies of potential new gene therapy for dry age-related macular degeneration
3 March 2025 - Avirmax Biopharma Inc, a clinical stage biopharmaceutical company developing next-generation gene therapies for retina diseases, announced on Friday that it has started an Investigation...
AbbVie receives positive CHMP opinion for upadacitinib in giant cell arteritis
28 February 2025 - Pharmaceutical company AbbVie (NYSE:ABBV) announced on Friday that it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for ...